Lantern Pharma Inc SEC Filings

Lantern Pharma Inc. has filed an S-1 to register up to 2,242,719 shares of common stock for resale by existing holders of warrants issued in a May 2026 financing. The company is not selling any new shares and will not receive proceeds from these resales.

Lantern may receive up to approximately $5.1 million if all registered warrants are exercised for cash at prices of $2.27 and $2.575 per share. As of March 31 2026 it held about $6.3 million in cash, cash equivalents and marketable securities and expects this to fund operations only until around the middle of the first quarter of 2027.

The company develops oncology drugs using its RADR A.I. platform and reports three clinical-stage small molecule candidates plus an ADC program. Its filings note recurring losses, negative operating cash flows and auditors’ substantial doubt about its ability to continue as a going concern without significant additional funding, alongside potential dilution and stock price volatility risks.

Lantern Pharma Inc. furnished an investor-style presentation used on June 1, 2026 to support discussions about the Harmonic™ Phase 2 clinical trial for its LP-300 product candidate. The presentation is attached as Exhibit 99.1 and is incorporated by reference for informational purposes.

The company notes that the material provided under this disclosure is considered "furnished," not "filed," which means it is not subject to certain liability provisions of the Exchange Act and is not automatically incorporated into other Securities Act or Exchange Act filings unless specifically referenced.

Lantern Pharma Inc. (LTRN) received an updated ownership report from a group of Bios-related investment entities and principals via Amendment No. 7 to their Schedule 13D. The group reports beneficial ownership of 571,305 shares of Lantern Pharma common stock, representing 4.48% of the outstanding shares.

These shares are held across several funds, including Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT, with entities such as Bios Advisors GP, Bios Capital Management, Bios Equity Partners and Bios Equity Partners II, and individuals Aaron G.L. Fletcher and Leslie W. Kreis deemed to share voting and dispositive power.

The percentages are calculated using 12,758,872 Lantern Pharma shares outstanding, based on 11,304,697 shares from a Form 10-K and 1,454,175 additional shares from a Form 8-K. The filing states that, aside from any exceptions described, only the reporting persons have rights to dividends or sale proceeds for the reported shares.

Lantern Pharma reported first quarter 2026 results showing tighter cost control while advancing its oncology and AI platforms. Research and development expenses fell to approximately $1.7 million, a 47% year-over-year reduction, and net loss narrowed to about $3.3 million, down 27%, or $0.30 per share.

Cash, cash equivalents, and marketable securities were about $6.3 million as of March 31, 2026, and a registered direct offering on May 14, 2026 added roughly $4.4 million in gross proceeds, which the company believes will fund operations into the middle of the first quarter of 2027.

Operationally, Lantern advanced its LP-300 HARMONIC trial with a successful FDA Type C meeting, obtained FDA IND clearance for Starlight Therapeutics’ pediatric CNS cancer trial, launched its multi-agentic AI co-scientist platform withZeta.ai commercially, expanded the predictBBB.ai platform, and outlined plans to separate withZeta.ai into an independent AI-focused entity.

Lantern Pharma reported a Q1 2026 net loss of $3.33 million, narrower than the $4.54 million loss a year earlier, as research and development spending fell to $1.72 million from $3.26 million. General and administrative costs rose modestly to $1.68 million.

Cash, cash equivalents and marketable securities totaled about $6.3 million as of March 31, 2026, with working capital of roughly $3.28 million. The company discloses “substantial doubt” about its ability to continue as a going concern without significant additional funding.

After quarter-end, Lantern raised gross proceeds of approximately $4.4 million through a registered direct equity offering and concurrent private warrants, and now estimates its liquidity will fund operations until around the middle of the first quarter of 2027. Lantern also plans to spin out its withZeta.ai AI platform into an independent, potentially publicly listed entity to pursue dedicated funding separate from its core oncology drug development programs.

Lantern Pharma Inc. entered into a registered direct offering and concurrent private placement raising approximately $4.4 million in gross proceeds. The company sold 1,454,175 common shares at $2.06 per share and issued pre-funded warrants for up to 681,748 shares at $2.0599 each, plus unregistered warrants to purchase up to 2,135,923 shares at an exercise price of $2.27 per share.

The warrants are exercisable starting six months after issuance and expire five years after first exercise, with exercise blocked above a 4.99% or 9.99% ownership cap. Lantern plans to use net proceeds for working capital and general corporate purposes. The company also outlined plans to separate its withZeta.ai AI platform and related assets into an independent entity that may seek its own stock exchange listing and give these investors rights to participate in up to 30% of certain future financings. Lantern agreed not to enter most variable-price financings for two years and temporarily suspended sales under its existing at-the-market program until a new prospectus supplement is filed.

Lantern Pharma Inc. director Lee Troy Schalop reported buying company securities. He acquired 48,544 shares of common stock at $2.06 per share in an open-market purchase, resulting in direct ownership of 48,544 shares after the transaction.

On the same date, he also acquired common stock purchase warrants covering 48,544 underlying shares, with a conversion or exercise price of $2.27 per share and an expiration date of November 13, 2031. According to the disclosure, these warrants were obtained in an offering of securities that closed on May 14, 2026 and will be exercisable starting on November 14, 2026.

Lantern Pharma Inc. director Jeffrey D. Keyser reported buying common stock and warrants. He acquired 48,544 shares of common stock in an open-market purchase at $2.06 per share, bringing his direct holdings to 94,303 shares. He also bought 48,544 common stock purchase warrants with an exercise price of $2.27 per share, each for 48,544 underlying shares of common stock. The securities were acquired in the company’s offering of securities that closed on May 14, 2026, and the warrants are exercisable starting November 14, 2026 and expire on November 13, 2031.

Lantern Pharma Inc. is offering 1,454,175 shares of common stock at $2.06 per share. The offering also includes pre-funded warrants to purchase up to 681,748 shares (exercise price $0.0001) available to purchasers who would otherwise exceed 4.99% (or elect 9.99%) ownership limits.

In a concurrent private placement, Lantern is issuing purchase warrants to buy up to 2,135,923 shares at an exercise price of $2.27 (not registered here). Gross proceeds from the registered component are $4,399,933.20 and estimated net proceeds to Lantern, before expenses, are approximately $4.09 million; Lantern estimates net proceeds after fees and expenses of approximately $3.94 million for use as working capital and general corporate purposes.